


ix.D  
H600.6 P928 88/1/16

# Texas Preventable Disease



# NEWS

Frank Bryant, Jr. MD, FAAFP  
Chairman  
Texas Board of Health

Robert Bernstein, MD, FACP  
Commissioner

**contents:**  
Clusters of H. influenzae Infection in Texas  
Day-care Facilities and TDH Recommendations  
for Prophylaxis

TEXAS STATE DOCUMENTS  
COLLECTION

**Bureau of Disease Control and Epidemiology,  
1100 West 49th Street, Austin, Texas 78756 (512-458-7455)**

## CLUSTERS OF H. INFLUENZAE INFECTIONS IN TEXAS DAY-CARE FACILITIES AND TDH RECOMMENDATIONS FOR PROPHYLAXIS

The Infectious Diseases Program of the Texas Department of Health is concerned about an increase in the number of reported secondary/subsequent *Haemophilus influenzae* type b (Hib) infections occurring in children attending Texas day-care facilities. By definition, both secondary and subsequent day-care cases are cases which occur from one to 60 days after a primary case in the same facility. A **secondary** case occurs in the same classroom as the primary case, whereas a **subsequent** case occurs in a different classroom. Through December 16, 1987, 19 Texas day-care facilities have reported clustering involving a total of 40 Hib infections among their attendees, including 18 primary, 2 co-primary, 16 secondary, and 4 subsequent infections.

### 1987 EXPERIENCE IN TEXAS

As of December 16, 1987, 15 day-care centers had a total of 16 **secondary** infections. The secondary cases occurred from two to 59 days following onset of the primary cases, with a median of eight days. One day-care facility in Travis County experienced both a secondary and a subsequent Hib infection 16 days following the primary case, and one Harris County facility experienced two secondary Hib infections eight days following the primary case. In three day-care facilities, it could be documented that the secondary case was either the only child or one of several children who did not receive rifampin prophylaxis.

Three day-care facilities in Williamson, Harris, and Dallas counties experienced **subsequent** cases occurring 7, 36, and 45 days, respectively, following onset of the primary case. The subsequent case in Dallas County proved interesting in that the primary and subsequent cases, both infants, were not exposed to one another in the same classroom, but they each had 3-year-old siblings who were in the same classroom at this day-care center.

One Dallas County day-care center reported two **primary** cases of *H. influenzae* meningitis in a single classroom with onset on the same day. All 19 classroom contacts were prophylactically treated with rifampin, and no secondary or subsequent cases were reported.

Although isolates were not available for outer membrane protein profiles, the cases in 12 of 19 day-care facilities had consistent antibiotic sensitivities. These data were not provided on cases in the remaining seven facilities.

### PREVIOUS EXPERIENCE (1980-1986) IN TEXAS

Until recently, clusters of Hib infections in Texas day-care centers rarely have been reported. In fact, no day-care clusters of Hib infections were reported to the TDH from the time surveillance of the disease began in 1980 until 1986 when one secondary infection in a day-care



facility was reported to the Infectious Diseases Program. This cluster involved a day-care center in Grayson County where a case of Hib meningitis/septicemia occurred in a child 51 days after a child in the same classroom experienced an Hib septic arthritis. Day-care classroom contacts were not prophylactically treated at the time of the primary case.

Prior to 1987, virtually all of the secondary cases reported to the Infectious Diseases Program have occurred in households. Five episodes of secondary disease among household contacts were reported in 1985, and in 1986, four episodes were reported. In 1987, only one report of secondary transmission in a household was received.

### 1987 ATTACK RATES IN TEXAS COMPARED TO OTHER STUDIES

Two recent prospective studies demonstrated an almost negligible risk of secondary transmission in day-care centers. Murphy, et al, reported a secondary attack rate in Dallas County of 0.17% (1/587) in children under 4 years of age, and Osterholm reported no secondary cases during a two-year study of 1,086 day-care contacts in Minnesota.<sup>1,2</sup> However, a cooperative study conducted in Seattle, Atlanta, and Oklahoma in 1983-84 showed a larger risk of secondary transmission in day-care centers for children younger than 2 years of age (10/755=1.3%), and a recent two-year prospective study in Oklahoma reported a secondary attack rate of 1.7% (5/292) in children under 2 years of age.<sup>3,4</sup>

Secondary classroom attack rates in Texas day-care centers in 1987 ranged from 0.9% (1/110) to 14.3% (1/7). The number of classroom contacts varied from seven to 110; median classroom size was 12. The lowest attack rate was reported in a facility with an "open concept" where all of the 110 children and 14 staff members mingled throughout most of the day. The Harris County day-care center which reported two secondary cases experienced a secondary classroom attack rate of 10.0% (2/20). Overall, a secondary attack rate of 5.2% (16/307) was reported for these Texas day-care cases. If only the secondary cases under 2 years of age and their classroom contacts were included (as in the Oklahoma study), the classroom attack rate was 7.9% (13/164).

### RECOMMENDATIONS FOR PROPHYLAXIS

Information provided to the Infectious Diseases Program indicates that the routine public health response to an Hib infection in a child attending a day-care facility varies greatly across the state. One reason for this diverse public health response is the difference between the American Academy of Pediatrics (AAP) and the Immunization Practices Advisory Committee (ACIP) recommendations for prophylaxis in day-care attendees. Although the AAP and the ACIP agree on prophylaxis recommendations when a case of Hib occurs in a household in which another child under 4 years of age resides (ie, that all members of the household, including adults and the index case, receive rifampin), the AAP and ACIP differ in their recommendations when a case occurs in a day-care setting. The AAP advises administering rifampin to all infants and supervisory personnel when two or more cases of invasive disease occur in a day-care group.<sup>5</sup> The ACIP, however, recommends that strong consideration should be given to administering rifampin prophylaxis to all children and staff in the day-care **classroom** in which one case of systemic Hib disease has occurred and in which one or more children under 2 years of age have been exposed.<sup>6</sup>

As in the past, the Texas Department of Health continues to support the ACIP guidelines for the prevention of secondary cases of Hib disease. Due to the current increase in secondary day-care center cases, it is imperative that local health authorities and physicians are reminded of the recommendations for prophylaxis.

# BACTERIAL MENINGITIS/SYSTEMIC INFECTION CASE INVESTIGATION FORM

## Texas Department of Health Epidemiology Division

<b>PERSONAL DATA</b>	<p>PATIENT'S NAME _____ AGE _____ SEX _____</p> <p>ADDRESS: _____ CITY: _____</p> <p>DATE OF BIRTH: ____/____/____</p> <p>RACE/ETHNICITY    WHITE _____;    HISPANIC _____;    BLACK _____;    AMERICAN INDIAN _____;    ASIAN _____;</p> <p>PHYSICIAN: _____ CITY: _____</p> <p>DATE OF ONSET ____/____/____    OUTCOME:    RECOVERED _____    DIED _____ (Date ____/____/____)</p>																																													
<b>HOSPITAL DATA</b>	<p>HOSPITAL: _____ DATE ADMITTED: _____</p> <p>CLINICAL ILLNESS (Please check all that apply):</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 33%;"><input type="checkbox"/> Meningitis</td> <td style="width: 33%;"><input type="checkbox"/> Septic Arthritis</td> <td style="width: 34%;"><input type="checkbox"/> <u>Neisseria meningitidis</u>; serotype _____</td> </tr> <tr> <td><input type="checkbox"/> Septicemia</td> <td><input type="checkbox"/> Pneumonia</td> <td><input type="checkbox"/> <u>Haemophilus influenzae</u>; serotype _____</td> </tr> <tr> <td><input type="checkbox"/> Cellulitis</td> <td><input type="checkbox"/> Pericarditis</td> <td><input type="checkbox"/> <u>Streptococcus pneumoniae</u></td> </tr> <tr> <td><input type="checkbox"/> Epiglottitis</td> <td><input type="checkbox"/> Other _____</td> <td>_____</td> </tr> </table> <p>Organism isolated from: _____ CSF; _____ BLOOD; _____ JOINT FLUID; _____ PLEURAL FLUID; _____ OTHER: _____</p> <p>ANTIBIOTIC SENSITIVITY STUDIES: (circle all that apply)</p> <table style="width: 100%; border: none;"> <tr> <td>Ampicillin/Penicillin</td> <td>S</td> <td>I</td> <td>R</td> <td>Not Done</td> <td rowspan="4" style="border-left: 1px solid black; padding-left: 10px;"> <table style="width: 100%; border: none;"> <tr> <th style="text-align: left;">Test</th> <th style="text-align: left;">Result</th> <th style="text-align: left;">Source of Specimen</th> </tr> <tr> <td>LA</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>CIE</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>Beta-lactamase</td> <td>_____</td> <td>(+)=resistant, (-)=sensitive</td> </tr> </table> </td> </tr> <tr> <td>Sulfadiazine</td> <td>S</td> <td>I</td> <td>R</td> <td>Not Done</td> </tr> <tr> <td>Rifampin</td> <td>S</td> <td>I</td> <td>R</td> <td>Not Done</td> </tr> <tr> <td>Chloramphenicol</td> <td>S</td> <td>I</td> <td>R</td> <td>Not Done</td> </tr> </table>	<input type="checkbox"/> Meningitis	<input type="checkbox"/> Septic Arthritis	<input type="checkbox"/> <u>Neisseria meningitidis</u> ; serotype _____	<input type="checkbox"/> Septicemia	<input type="checkbox"/> Pneumonia	<input type="checkbox"/> <u>Haemophilus influenzae</u> ; serotype _____	<input type="checkbox"/> Cellulitis	<input type="checkbox"/> Pericarditis	<input type="checkbox"/> <u>Streptococcus pneumoniae</u>	<input type="checkbox"/> Epiglottitis	<input type="checkbox"/> Other _____	_____	Ampicillin/Penicillin	S	I	R	Not Done	<table style="width: 100%; border: none;"> <tr> <th style="text-align: left;">Test</th> <th style="text-align: left;">Result</th> <th style="text-align: left;">Source of Specimen</th> </tr> <tr> <td>LA</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>CIE</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>Beta-lactamase</td> <td>_____</td> <td>(+)=resistant, (-)=sensitive</td> </tr> </table>	Test	Result	Source of Specimen	LA	_____	_____	CIE	_____	_____	Beta-lactamase	_____	(+)=resistant, (-)=sensitive	Sulfadiazine	S	I	R	Not Done	Rifampin	S	I	R	Not Done	Chloramphenicol	S	I	R	Not Done
<input type="checkbox"/> Meningitis	<input type="checkbox"/> Septic Arthritis	<input type="checkbox"/> <u>Neisseria meningitidis</u> ; serotype _____																																												
<input type="checkbox"/> Septicemia	<input type="checkbox"/> Pneumonia	<input type="checkbox"/> <u>Haemophilus influenzae</u> ; serotype _____																																												
<input type="checkbox"/> Cellulitis	<input type="checkbox"/> Pericarditis	<input type="checkbox"/> <u>Streptococcus pneumoniae</u>																																												
<input type="checkbox"/> Epiglottitis	<input type="checkbox"/> Other _____	_____																																												
Ampicillin/Penicillin	S	I	R	Not Done	<table style="width: 100%; border: none;"> <tr> <th style="text-align: left;">Test</th> <th style="text-align: left;">Result</th> <th style="text-align: left;">Source of Specimen</th> </tr> <tr> <td>LA</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>CIE</td> <td>_____</td> <td>_____</td> </tr> <tr> <td>Beta-lactamase</td> <td>_____</td> <td>(+)=resistant, (-)=sensitive</td> </tr> </table>	Test	Result	Source of Specimen	LA	_____	_____	CIE	_____	_____	Beta-lactamase	_____	(+)=resistant, (-)=sensitive																													
Test	Result	Source of Specimen																																												
LA	_____	_____																																												
CIE	_____	_____																																												
Beta-lactamase	_____	(+)=resistant, (-)=sensitive																																												
Sulfadiazine	S	I	R	Not Done																																										
Rifampin	S	I	R	Not Done																																										
Chloramphenicol	S	I	R	Not Done																																										
<b>EXPOSURE</b> <small>(for meningococcal and H. influenzae infections only)</small>	<p>1. Did the patient ever receive the Hib vaccine? YES _____; NO _____ IF YES: DATE OF VACCINATION _____</p> <p>2. Did any member of patient's household have a similar illness during the 60 days before this patient's illness? YES _____ NO _____</p> <p style="margin-left: 20px;">If YES, provide NAME: _____ Age _____ Relationship _____ Date _____</p> <p>3. Total # <u>household</u> contacts: _____ How many given prophylaxis? _____ Dates of prophylaxis? _____</p> <p>4. Did the patient attend/work at a day-care center/home during the 60 days before onset of illness? YES _____ NO _____</p> <p style="margin-left: 20px;">If YES, Name of CENTER/HOME: _____ ADDRESS: _____ Date last Attended: _____</p> <p>5. Total # <u>classroom</u> contacts: STUDENTS _____ STAFF _____ How many given prophylaxis? STUDENTS _____ STAFF _____</p> <p>6. Type of prophylaxis: _____ Inclusive dates of prophylaxis: _____</p> <p>7. Total enrollment of day-care center: _____ Total # of staff: _____ Total # prophylactically treated: _____</p> <p>8. Did any other child in center have a similar illness during the 60 days before this patient's illness? YES _____ NO _____</p> <p style="margin-left: 20px;">If YES, provide NAME(S) of primary case: _____ (Please fill out a case investigation form for this primary case.)</p>																																													

(Prophylaxis recommendations on reverse)

PROPHYLAXIS RECOMMENDATIONS

When prophylaxis is indicated, it should be administered to all eligible contacts at the same time to eliminate the organism from that population. Prophylaxis should begin within 24 hours of diagnosis or strong suspicion of case. Culturing contacts is not recommended. Prophylaxis should not substitute for close observation of case contacts for symptoms.

Neisseria meningitidis (meningococcus, gram negative diplococcus); incubation period is usually 3-4 days but can vary from 2-10 days.

Who should receive prophylaxis?

- All "family contacts" or household members who spend at least 8 hours a day with the case.
- Classroom contacts in the day-care center or day-care home attended by the case.
- Only hospital personnel who examine the throat, intubate, suction, or give mouth-to-mouth resuscitation to the case should receive prophylaxis.

Rifampin Dosage\*

- Adults: 600 mg PO twice a day x 2 days
- Infants and children (1 month-12 years): 10 mg/kg\*\* PO twice a day x 2 days
- Infants under 1 month: 5 mg/kg PO twice a day x 2 days.

Sulfadiazine Dosage: Use only if the organism has already been cultured and shown sensitive to sulfas.

- Adults: 1 gram PO twice a day x 2 days
- Children: (1-12 years of age): 500 mg PO twice a day x 2 days
- Infants (< 12 months): 500 mg PO once a day x 2 days.

In addition to the routine medications used to treat meningococcal infections, the index case should receive one of the above regimens before going home from the hospital in order to eradicate pharyngeal carriage of the N. meningitidis.

Haemophilus influenzae (H. flu) (small gram-negative rods); incubation period is short, usually 2-4 days.

Who should receive prophylaxis?

- All "family contacts" ( members of the patient's household) if there is another child under 4 years of age residing in the home.
- Prophylaxis should strongly be considered for all staff and children--regardless of age--in the day-care classroom in which a case of systemic Hib disease has occurred, and in which one or more children under 2 years of age have been exposed.
- Children in the day-care classroom who have been vaccinated with the Hib vaccine should also receive rifampin.
- Hospital personnel do not need prophylaxis.

Rifampin Dosage:\*

- Adults: 600 mg PO once a day x 4 days
- Infants and children (1 month-12 years): 20 mg/kg\*\* PO once a day x 4 days

In addition to the routine medications used to treat H. influenzae infections, the index case should receive the above regimen before going home from the hospital in order to eradicate pharyngeal carriage of the organism.

\* Before administering rifampin, note that rifampin:

- is not recommended for use during pregnancy
- interferes temporarily with effectiveness of oral contraceptives
- will turn urine, tears, saliva an orange/red color; soft contact lenses will be permanently stained if worn while taking rifampin.

\*\* The maximum dosage of rifampin should not exceed a total of 600 mg per dose.

COMMENTS

Investigated by: \_\_\_\_\_  
 Agency: \_\_\_\_\_  
 Telephone: \_\_\_\_\_  
 Date: \_\_\_\_\_

RETURN COMPLETED FORM TO:

Infectious Diseases Program  
 Epidemiology Division  
 Texas Department of Health  
 1100 West 49th Street  
 Austin, TX 78756-3180

The TDH recommends rifampin prophylaxis for all staff and children, regardless of age, in the day-care classroom in which a case of systemic Hib disease has occurred and in which one or more children under 2 years of age have been exposed. Rifampin prophylaxis is effective in preventing secondary cases in day-care settings. However, prophylaxis of classroom contacts must: 1) begin as rapidly as possible, though no later than 14 days after last contact with the first case; 2) include at least 75% of the classroom contacts to be effective; and 3) include children who have received the Hib vaccine. Failure to meet these conditions may increase the risk of secondary transmission.

#### REPORTING OF HIB INFECTIONS -- THE CASE INVESTIGATION FORM

The Communicable Disease Prevention and Control Act (Texas Civil Statutes, Article 4419b-1) requires that all invasive ("systemic") infections by *H. influenzae* be reported to the Texas Department of Health. These include meningitis, septicemia, cellulitis, epiglottitis, septic arthritis, osteomyelitis, pericarditis, and pneumonia. Otitis media and conjunctivitis due to *H. influenzae* are not considered invasive disease and should not be reported to health officials.

The Bacterial Meningitis/Systemic Infection Case Investigation form (MENING-1, revised 12/87) is included in this issue of PDN and is available upon request from the Infectious Diseases Program, Epidemiology Division, TDH. Local and regional health department personnel are strongly encouraged to use this form when following up systemic infections caused by *H. influenzae* or *Neisseria meningitidis* (meningococcal infections). The TDH recommendations for prophylaxis are printed on the back of the form. The Infectious Diseases Program suggests the following priority for completion of case investigation forms:

1. A systemic *H. influenzae* or *N. meningitidis* infection in a child attending any day-care facility (licensed day-care center, day-care home, or private babysitter where more than one child is cared for).
2. A systemic *H. influenzae* infection in any child under 6 years of age.
3. A death in a patient of any age resulting from a systemic *H. influenzae* infection.
4. Any systemic *H. influenzae* infection.

Please send the completed forms to the Infectious Diseases Program, Texas Department of Health, 1100 W. 49th Street, Austin, TX 78756-3180. These reports are essential to the Infectious Diseases Program in order to assess the actual occurrence of *H. influenzae* infections in Texas day-care facilities.

---

Prepared by: Jan Pelosi, Epidemiologist Assistant, Infectious Diseases Program, Epidemiology Division, Texas Department of Health.

#### REFERENCES:

1. Murphy TV, Clements EJ, Breedlove JA, et al. Risk of subsequent disease among day-care contacts of patients with systemic *Haemophilus influenzae* type b disease. N Engl J Med 1987;316:5-10.
2. Osterholm MT, Pierson LM, White KE, et al. The risk of subsequent transmission of *Haemophilus influenzae* type b disease among children in day care: results of a two-year statewide prospective surveillance and contact survey. N Engl J Med 1987;316:1-5.

3. Fleming DW, Leibenhaut MH, Albanes D, et al. Secondary *Haemophilus influenzae* type b in day-care facilities: risk factors and prevention. JAMA 1985;254:509-15.
4. Makintubee S, Istre GR, Ward JI. Transmission of invasive *Haemophilus influenzae* type b disease in day care settings. J Pediatrics 1987;111:180-6.
5. *Haemophilus influenzae* infections. In: Report of the Committee on Infectious Diseases, 20th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1986:169-74.
6. Immunization Practices Advisory Committee (ACIP). Update: prevention of *Haemophilus influenzae* type b disease. MMWR 1986;35(11):170-4,179-80.

---

TEXAS PREVENTABLE DISEASE NEWS (ISSN 8750-9474) is a free, weekly publication of the Texas Department of Health, 1100 West 49th Street, Austin, TX 78756. Second-class postage paid at Austin, TX. POSTMASTER: Send address changes to TEXAS PREVENTABLE DISEASE NEWS, 1100 West 49th Street, Austin, TX 78756.

---

**TEXAS PREVENTABLE DISEASE NEWS**  
Texas Department of Health  
1100 West 49th Street  
Austin, TX 78756

**SECOND CLASS POSTAGE**  
**PAID AT AUSTIN, TX**

**RETURN POSTAGE GUARANTEED**



**Have Annual  
Check-Ups**